HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside

Narrative Update on Henry Schein

The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street.

Analyst Commentary

Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance. Price targets cluster around the high $80s to low $100s, reflecting different views on execution, earnings power, and end market trends.

Bullish Takeaways

Bullish analysts point to Q4 results and initial FY26 guidance coming in better than expected, which they see as support for a higher fair value range in their models.
Some bulls cite improving visibility on growth after the Q4 report, including comments about better patient demand and what they view as signs of an improving end market.
Several target increases into the $90 to around $100 range are tied to updated earnings models, suggesting confidence in Henry Schein's ability to execute on its plan and potentially expand earnings over time.
Upbeat views highlight stable results, some share gain and what they describe as modest rebound in demand, which they use to justify Outperform or Overweight ratings alongside higher price targets.

Bearish Takeaways

Bearish analysts and those with neutral or Hold ratings maintain more cautious targets, in some cases reducing prior price objectives, reflecting concerns about how much upside is already reflected in current valuation.
Some research describes the overall results as stable but not fully thesis changing, which signals a view that execution is solid but not enough to justify more aggressive earnings or valuation assumptions.
Neutral stances paired with target moves into the mid to high $80s indicate that while Q4 updates influenced models, these analysts still see limited upside relative to their risk and reward frameworks.
Cautious commentary around end markets, even with signs of improvement, suggests that a portion of the Street is still waiting for more consistent evidence before assigning higher valuation multiples.

What’s in the News

Henry Schein reported an impairment charge on intangible assets of US$15 million for the fourth quarter ended December 27, 2025 (company disclosure).
The company issued earnings guidance for 2026, with total sales growth expected to be approximately 3% to 5% over 2025 (company guidance).
From September 28, 2025 to December 27, 2025, Henry Schein repurchased 2,812,872 shares, representing 2.37% of shares, for US$200 million (company buyback update).
Since the buyback program announced on December 13, 2018, Henry Schein has repurchased a total of 41,687,251 shares, representing 31.37% of shares, for US$2.97 billion (company buyback update).

Valuation Changes

Fair Value: The updated estimate has moved from about $89.23 to about $90.21 per share, a slight increase in the modeled fair value range.
Discount Rate: The rate is essentially unchanged at about 6.98%, indicating no material change in the assumed risk profile used in the valuation work.
Revenue Growth: The long-term modeled revenue growth rate has shifted from about 3.78% to about 3.81%, a very small upward adjustment.
Net Profit Margin: The assumed net profit margin has moved from about 4.04% to about 3.85%, a modest reduction in expected profitability levels.
Future P/E: The assumed future P/E multiple has moved from about 17.43x to about 18.49x, indicating a slightly higher valuation multiple in the updated model.

0 views

Key Takeaways

Focus on high-margin segments, digital transformation, and operational efficiencies is expected to boost margins and earnings growth.
Demographic shifts and industry consolidation are likely to drive sustained demand and enhance customer loyalty in key markets.
Margin pressures from competitive pricing, staffing constraints, regulatory hurdles, and execution risks could limit revenue growth and profitability despite stabilization efforts in key business areas.

Catalysts

About Henry Schein

Provides health care products and services to office-based dental and medical practitioners, and alternate sites of care worldwide.What are the underlying business or industry changes driving this perspective?

The company is experiencing strong growth in high-margin businesses such as Specialty Products, Technology, and private-label offerings, and expects over 50% of non-GAAP operating income to come from these segments-supporting structurally higher gross margins and likely driving earnings expansion.
Investments in digital workflow, AI solutions, and integrated cloud-based practice management platforms are accelerating recurring SaaS revenues and client retention, positioning Henry Schein to benefit from the ongoing digital transformation of healthcare, which should support both revenue growth and improved margins.
Henry Schein is actively pursuing operational efficiencies-including $100M+ cost savings run-rate by end of 2025 and further value creation initiatives led by KKR's Capstone-which are expected to lower operating expenses and drive net margin improvement from 2026 onward.
Continued expansion of the company's Home Solutions platform to meet increased demand for at-home healthcare, coupled with robust demographic drivers from an aging global population, are anticipated to support sustained volume growth in core distribution and specialty lines, providing a foundation for long-term revenue growth.
Dental and medical practice consolidation is increasing client reliance on integrated supply, technology, and value-added service partners like Henry Schein, enhancing share gains and customer stickiness across both the U.S. and international markets-with positive implications for top-line growth and earnings stability.

Henry Schein Earnings and Revenue Growth

Henry Schein Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Henry Schein's revenue will grow by 3.8% annually over the next 3 years.
Analysts assume that profit margins will increase from 3.0% today to 3.8% in 3 years time.
Analysts expect earnings to reach $567.5 million (and earnings per share of $5.04) by about April 2029, up from $398.0 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as $652.2 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 18.7x on those 2029 earnings, down from 22.4x today. This future PE is lower than the current PE for the US Healthcare industry at 24.3x.
Analysts expect the number of shares outstanding to decline by 5.76% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Persistent competitive pricing pressures, especially in key categories like gloves (where pricing remains very competitive and still below previous year levels), could continue to weigh on distribution gross margins, reducing profitability and potentially hindering earnings growth even as volume stabilizes.
Flat to modest dental patient traffic and ongoing staffing shortages (notably in hygienists and office support) are constraining underlying volume growth in the core dental business globally, which limits organic revenue expansion and exposes results to macroeconomic or reimbursement shocks in key markets.
Greater customer price sensitivity due to tariffs and the potential for large DSO/group customers to actively RFP portions of their business places greater bargaining power with customers, risking margin compression and slower top-line growth if Henry Schein cannot fully offset price concessions with its owned brands or value-added services.
International expansion, while producing some bright spots, faces country-specific regulatory challenges (e.g. recent law changes in France), currency volatility, and localized competition, all of which could restrict anticipated revenue diversification and net earnings contribution from outside the U.S.
The multi-year leadership transition and implementation of cost-saving/value creation initiatives with KKR/consulting partners carry significant execution risk; delays, integration hurdles, or cultural disruption could impair near-term efficiency gains, and if technology or AI investments lag or under-deliver, Henry Schein could lose share to more innovative or nimble competitors, pressuring long-term earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $90.21 for Henry Schein based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $104.0, and the most bearish reporting a price target of just $64.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $14.8 billion, earnings will come to $567.5 million, and it would be trading on a PE ratio of 18.7x, assuming you use a discount rate of 7.0%.
Given the current share price of $77.54, the analyst price target of $90.21 is 14.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Henry Schein?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook